Market research
EMD.AU Emyria Limited
AU AUD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 39M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.03
Profile
Company facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Health Information Services
- ISIN
- AU0000073645
- Market cap
- 39M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.03
About
About Emyria Limited
Emyria Limited engages in delivering and developing of treatments for mental health and select neurological conditions in Australia. The company operates through Clinical Services, Clinical Services, and corporate segments. It provides therapy programs for post-traumatic stress disorder (PTSD) and treatment-resistant depression. The company also develops ultra-pure CBD capsules (EMD-RX7, and EMD-RX9) and proprietary MDMA analogues, as well as provides psychological trauma care facility under the Pax Centre name. It has a collaboration partnership with the University of Western Australia to support the expand Emyria's MDMA analogue drug development program. The company was formerly known as Emerald Clinics Limited and changed its name to Emyria Limited in September 2020. Emyria Limited was incorporated in 2018 and is headquartered in Subiaco, Australia.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the EMD.AU discussion.
5 years, 5 months ago
Emyria Limited is currently in a long term uptrend where the price is trading 23.8% above its 200 day moving average.
From a valuation standpoint, the stock is 87.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 31.5.
Based on the above factors, Emyria Limited gets an overall score of 2/5.